Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalamine 2g ER Granules for Maintenance of Remission in UC
NCT02522780Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Feb 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of Salcrozine in ulcerative colitis (UC), sponsored by Ferring Pharmaceuticals. Started Feb 2016; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02522780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522780.